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COPD is a diverse disease entity with multiple dimensions that uniquely define the patient’s
performance, morbidity and mortality. FEV1 is both the traditional metric used to define the
progression of COPD as well as the strongest spirometric predictor of mortality in COPD
patients. However, besides pulmonary functional abnormalities, COPD is also associated with
significant systemic effects. Therefore, the global assessment of an affected patient should
include different aspects of the consequences of this disorder, beyond the ‘‘gold-standard’’
assessment of airflow limitation. Quantification of the patient’s dyspnea, body composition
as expressed by BMI, simple measures of exercise capacity such as the 6MWD, assessment of
comorbidities and identification of characteristics related to different phenotypes are features
that may lead to more optimal management of such patients.
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COPD is a major cause of morbidity and disability worldwide
and is the fourth leading cause of death in the USA and
Europe.1,2 FEV1 is both the traditional metric used to define
the progression of COPD and the strongest spirometric
predictor of mortality in COPD patients.3 Factors that
affect decline in FEV1 are therefore of prognostic impor-
tance in COPD.4 However, besides pulmonary functional
abnormalities, COPD is also associated with significant
effects outside the lungs, such as malnutrition, pulmonary
hypertension and peripheral muscle weakness, the so-
called systemic effects of COPD.5,6 The negative impact of
COPD on patient’s quality of life has led to the need of
developing alternative tools for the assessment of the COPD
patient. It is currently understood that the broad term
COPD comprises several clinical phenotypes, including
patients with persistent hypoxemia, patients characterized
by emphysema and marked hyperinflation, patients with
frequent exacerbations, and patients with peripheral
muscle dysfunction.7 The differences between such
patients render a more global assessment of COPD imper-
ative. The aim of the present review is to focus on
complementary and/or alternative methods of assessment
of the individual COPD patients beyond the gold-standard
FEV1, in order to evaluate better the disease severity and
predict their prognosis. The parameters that are discussed
are the ones that, according to the authors’ point of view,
are closest to clinical application.
Simple spirometry
Spirometry is the most widely used non-invasive test of
pulmonary function and provides an overall assessment of
lung function and an objective method for following disease
progression or improvement and therapeutic response over
time.8 The post-bronchodilator forced expiratory volume in
1 s (FEV1) has been used as the gold-standard for the
diagnosis and classification of COPD.2 Furthermore, FEV1
has been used as a marker for the description of disease
severity, and progression.2,9 FEV1 is also being used as
a marker for evaluating the effect of treatment, althoughthis seems paradoxical since COPD is diagnosed on the basis
of a low FEV1 that is poorly reversible after bronchodilator
therapy.2 The change in FEV1 following bronchodilator
therapy is poorly predictive of improved symptoms and
exercise capacity in advanced COPD10 while several thera-
peutic agents such as rehabilitation improve symptoms in
COPD patients without modifying FEV1.
11 Post-bronchodi-
lator FEV1 is more reproducible than pre-bronchodilator
values,12 with an increase of 200 mL plus 12% of the base-
line value representing the minimal clinically important
difference. Over 50% of COPD patients present significant
bronchodilator reversibility, however this response changes
with time in a significant proportion of them and does not
predict disease progression and response to treatment.13
The forced expiratory volume in 6 s (FEV6) has been
proposed as an alternative to forced vital capacity (FVC)
that is both reproducible and acceptable for the evaluation
of airflow obstruction,14 and may predict lung function
decline in adult smokers.15 It has been suggested that the
FEV1/FEV6 ratio may be a more appropriate measure of
airflow obstruction than FEV1/FVC,
16 yet FEV1/FVC ratio
represents a globally accepted measure that has been
adopted by current guidelines. Despite the wide criticism
over FEV1/FVC ratio, based on the fact that it may over-
diagnose COPD in older populations, data from the
Cardiovascular Health Study suggest that a fixed FEV1/FVC
ratio of <0.70 may identify patients who are at greater risk
for death and hospitalization from COPD, even among older
adults.17 Based on the above, an FEV1/FVC ratio <0.70
remains not only the guideline-suggested gold-standard for
the diagnosis of COPD, but also a clinically significant
measurement.Other pulmonary function tests
In patients with COPD the loss of lung elastic recoil and
development of expiratory flow limitation promote
progressive air trapping with an increase in inspiratory
capacity (IC). Static lung hyperinflation increases during
exercise and has been associated with limitations in the
functional capacity of COPD patients.18 Lung hyperinflation
can be evaluated by the inspiratory capacity to total lung
Table 1 The modified Medical Research Council dyspnea
scale (MMRC).35
Grade of dyspneaSymptoms
Grade 0 Not troubled by breathlessness except on
strenuous exercise
Grade 1 Short of breath when hurrying or walking
up a slight hill
Grade 2 Walks slower than contemporaries on the
level because of breathlessness or has to
stop for breath when walking at own pace
Grade 3 Stops for breath after walking 100 m or
after a few minutes on the level
Grade 4 Too breathless to leave the house or
breathless when dressing or undressing
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ratio correlates to the patients’ dyspnea and exercise
tolerance and can be used as a predictor of mortality in
COPD.19 Those findings suggest that the IC/TLC ratio may
reflect the overall impact of disease severity and repre-
sents a marker that could be useful for the multidimen-
sional evaluation of COPD.19
The single-breath diffusing capacity of the lungs for
carbon monoxide (DLCO) is frequently used in the differ-
ential diagnosis of patients with dyspnea in the clinical
setting.20 The diffusing capacity is a very useful measure-
ment in the assessment of COPD because is the best
pulmonary function test which represents the integrity of
the pulmonary capillary bed.21 In the COPD patients, in
particular, DLCO correlates with the degree of emphysema
on computed tomography of the lung,22 and may be used as
an easily repeatable, non-invasive indicator of the emphy-
sema COPD phenotype. The technique used has been
standardized,23 however a dedicated laboratory with
experienced personnel is necessary.24
Arterial blood gas analysis is important to determine the
presence of hypoxemia and hypercapnia. It is not neces-
sary for all COPD patients, since it is recommended for
patients with an FEV1< 50% predicted and symptoms and/
or signs indicative of respiratory failure or right heart
failure.2 In that case, it is necessary to determine the
patients in need for supplementation of long-term oxygen
therapy that will improve their life span.2 For the rest of
the patients, screening with a pulse oximeter is considered
as adequate.
Radiological evaluation
Chest X-ray can provide signs that are associated to the
presence of COPD,2 yet in the majority of cases it is not
diagnostic for COPD unless obvious bullous disease is
present. However, chest X-ray is very important for the
exclusion of alternative diagnoses and/or comorbidities,
such as heart failure25 and lung cancer,26 both being
common in smokers, and therefore it may be recom-
mended in the initial evaluation of a COPD patient. In
contrast, computed tomography of the chest is not
routinely recommended for COPD patients. However, it has
been shown that the severity of emphysema varies among
patients with the same stage of COPD,27 and given the fact
that high resolution computed tomography (HRCT) scans
can detect earlier disease than airflow obstruction or
changes in diffusing capacity28 it may be helpful for the
diagnosis of early stages of COPD in patients with
preserved lung function.28 Additionally, chest HRCT is
necessary for the diagnosis of upper lobe distribution of
emphysema and the referral of patients for lung-volume
reduction surgery.1,2
Quantification of dyspnea
Dyspnea is a subjective perception of respiratory discom-
fort and is a result of multifaceted mechanisms, which
include abnormalities in the respiratory control system,
neurochemical receptors, ventilation, respiratory muscles
and gas exchange.29 Dyspnea is another variable that needsto be determined in primary care, because it is closely
related to patients’ life and for that reason the evaluation
of dyspnea should be included among standard measures of
physiologic lung function.30 Dyspnea can vary among
patients with the same degree of airway obstruction as
differences in languages, in races, cultures, gender, and in
the manner in which concepts or symptoms are held can all
influence the idea, quality and intensity of dyspnea.29
Categorizing patients with COPD on the basis of the level of
dyspnea has been shown to be a better predictor of 5-year
survival than the classification on the basis of disease
severity, as assessed by the percentage of predicted FEV1.
31
Furthermore, categorization on the basis of the level of
dyspnea gives a better estimate of disability and health-
related quality of life in COPD patients.32,33 Finally, it has
been shown that the initial degree of dyspnea of a COPD
patient is determinative for its improvement in exercise
performance and health status after a program of pulmo-
nary rehabilitation.34 Therefore, the level of dyspnea, in
addition to the level of airway obstruction, may provide
clinically important information in the management of
patients with COPD.31
There are several ways to assess dyspnea in clinical
practice, while it takes only a few minutes and can be
easily evaluated while taking patients’ history. The esti-
mation of the level of dyspnea during activities of daily
living can be achieved by using several clinical dyspnea
ratings. The ones more commonly used in clinical practice
is the modified Medical Research Council (MRC) scale for
the evaluation of dyspnea in everyday activities (Table 1)35
and the Borg scale for the quantification of dyspnea on
exertion.36 Finally, the assessment of the influence of
dyspnea on health-related quality of life can be evaluated
using a disease-specific questionnaire such as the St.
George’s Respiratory Questionnaire.37
Body composition
One of the most common consequences of COPD is the
nutritional abnormalities that present as weight loss and
skeletal muscle loss and dysfunction.38 Some of the main
potential mechanisms of skeletal muscle mass loss and
dysfunction in COPD include physical inactivity due to
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protein synthesis), systemic inflammation (which increases
muscle cell apoptosis) and increased levels of oxidative
stress (especially during disease exacerbations) which
causes muscle fatigue and facilitates proteolysis.38
The body mass index (BMI, which is calculated as weigh/
height squared in kg/m2) is an established independent
prognostic factor in COPD, and a lower BMI (i.e. less than
21 kg/m2) is associated with greater risk of death irre-
spective of the stage of the disease.39,40 COPD patients with
mild to moderate COPD have better prognosis if they are
normal or overweight, whereas in severe COPD being
overweight and even obese is associated with a better
survival.39 Changes in BMI also seem to have an impact in
survival, as it has been observed that weight loss in COPD is
an independent risk factor of all cause mortality, while
weight gain seems to have a protective effect in under-
weight and normal-weight subjects with severe COPD.41
The body mass can be divided into two compartments:
fat mass and fat free mass (FFM). The first serves as
a metabolic inactive energy store, whereas the latter
contains the metabolic active organs, among which skeletal
muscles are the largest part.42 Body composition can be
determined with several methods such as measurement of
bioelectrical impedance (BIA), dual-energy X-ray absorpti-
ometry (DEXA), or underwater weighting. It has been
proposed that BIA has a better precision among non-obese
patients and DEXA in obese patients.43 Importantly, alter-
ations in body composition can occur in COPD patients in
the absence of clinically significant weight loss, and include
loss of fat free mass and bone mineral content.38 Low FFM
(i.e. less than 16 kg/m2) is common in patients with COPD
and is related to greater mortality, even in patients with
normal BMI.42,44 Furthermore, the decline in FFM in COPD
patients is associated with worse lung function and
frequent exacerbations.45 The fat free mass index (FFMI,
which is calculated as FFM/height squared) reflects better
the skeletal muscle mass in patients with COPD and has
been recently shown to correlate to dyspnea, airways
obstruction and exercise capacity.46 In support of those
observations, another study has shown in a cohort of 162
COPD patients that a simple measurement of quadriceps
strength represents a better predictor of mortality
compared to age, FEV1 and BMI.
47 BMI still represents the
easiest measurement, yet an evaluation of body composi-
tion and/or skeletal muscle strength may provide addi-
tional information and identify individuals in need for
nutritional support and exercise intervention.48
Exercise capacity
Patients with COPD frequently report dyspnea related to
everyday tasks and are markedly inactive in daily life.49
This symptom-induced inactivity is an additional factor that
leads to deconditioning and muscle weakness.50 Several
laboratory tests are available for the objective evaluation
of functional exercise capacity, such as the cardiopulmo-
nary exercise testing, the Shuttle Walk Test and the 6-
minutes walking test. Cardiopulmonary exercise testing is
considered the gold-standard in the evaluation of patients
with pulmonary diseases as it is monitoring breath bybreath several cardiopulmonary variables, including
maximal oxygen uptake, pulmonary output of CO2, minute
ventilation, and cardiac frequency.51 However, cardiopul-
monary exercise testing requires dedicated laboratory
equipment and expertise, therefore it cannot be suggested
for everyday clinical practice.
In the past years, simpler tests of exercise capacity have
been implemented in the evaluation of COPD patients. In
the Shuttle Walk Test the patient walks around a 10-m
circuit at a pace set by an audible signal, that is ramped up
each minute. The end-point is the distance that the patient
has walked when they can no longer keep pace with the
signal.52 However, the test that has gained importance
globally in the assessment of patients with COPD is the 6-
minute walk test, which has proven to be reliable, safe and
easy to apply.53 The primary measurement of this test is the
total distance that can be walked in 6 min; secondary
measures include oxygen saturation which is measured via
pulse oximetry, as well as dyspnea and fatigue that are
measured using a Borg or a visual analog scale.54 The 6-
minute walking distance (6MWD) has been shown to be an
independent predictor of mortality in COPD patients, as
shorter walked distance was confirmed to be associated
with a higher mortality.55 A recent report from the same
group has shown that the 6MWD declines over time and that
this decline is most important in patients with severe
airflow limitation (i.e. FEV1< 50% predicted).
56 Interest-
ingly, in patients with severe COPD the decrease in FEV1
over time has been shown to be relatively small,56 sug-
gesting that decline in exercise capacity occurs indepen-
dently from changes in lung function.55 According to the
above, it is clear that 6MWD can help describe clinical
changes that are not detectable with the use of pulmonary
function tests alone, especially in severe and very severe
COPD.
Health-related quality of life (HRQoL)
Health-related quality of life (HRQoL) is a subjective
measurement based on an individual perception of alter-
ations in life satisfaction due to problems with health. In
patients with advanced lung disease, HRQoL reflects the
impact of the disease and its management, in combination
with the existing comorbidities, on the ability of a person to
perform or enjoy activities of daily living.57 Over the past
years, more and more research has been undertaken in
order to quantify the impact of disease on daily life and
well-being of COPD patients. The main instruments used to
evaluate HRQoL are the Medical Outcomes Study Short
Form 36 (SF-36) and St George’s Respiratory Questionnaire
(SGRQ), a generic and a disease-specific Questionnaire,
respectively.37,58
HRQoL outcomes are very important in all aspects of
COPD because they are felt to represent changes that are
clinically most relevant to patients and that may not be
measurable by other more conventional parameters.59
Impaired exercise performance and functional capacity are
quite strongly associated with poorer health status.60
Several factors may have effect in the HRQoL. For example,
patients with abnormally low or high body weight, as well
as patients with low lean mass, were found to have poorer
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COPD tend to present with worse HRQoL,62 the correlation
between health status, as expressed by the SGRQ, and FEV1
in COPD patients is weak; however, it has been reported
that the total score in SGRQ can be attributed to a combi-
nation of cough, wheeze, MRC dyspnea grade, 6MWD, and
anxiety score.60 Moreover, health status measurements are
associated to exacerbation frequency, reflecting the
impact of exacerbations on COPD patients’ everyday life.63
Finally, health status questionnaires have been used for the
assessment of the effect of treatment interventions in
prospective clinical trials.64 The minimal clinically impor-
tant difference in the SGRQ that is related with a clinically
significant reduction in symptoms and the impact of the
disease on a patients’ daily life is a change of 4 units.60
According to the above, health status questionnaires can
bring together a wide range of effects of COPD into one
comprehensive measure. However, they are time-
consuming for the busy clinician to perform and they
represent currently mainly research tools.
Biomarkers of inflammation
COPD is associated with both airway and systemic inflam-
mation.4 Airway inflammatory markers are higher in more
severe disease and increase during COPD exacerbations.4
However, despite the widespread use of exhaled biomarkers
in patients with asthma and their use in clinical practice,65,66
no exhaled biomarker has been widely used in clinical trials
in COPD. In contrast, there is evidence that shows that
systemic inflammation is present in stable COPD and that the
intensity of the inflammatory process relates to the severity
of the underlying disease.67 Several inflammatory markers
such as C-reactive protein (CRP), fibrinogen and IL-6, are
increased in patients with COPD in both stable disease and
exacerbations,4,68,69 with CRP being the most studied
biomarker. A study has connected elevated CRP levels with
increased resting energy expenditure and reduced exercise
capacity,70 whereas an epidemiologic study from the
Copenhagen City Heart Study has shown that CRP is an
independent predictor of COPD hospitalizations and death.68
However, in a recent prospective cohort study of patients
withmoderate to very severe COPD followed-up for amedian
of 36 months, CRP was not significantly associated with
survival.71 Despite the fact that COPD is a systemic disease
and has recently been suggested to be a part of a chronic
systemic inflammatory syndrome,72 no systemic biomarker
can be suggested yet for the routine evaluation of COPD
patients,with CRP being the single possible exception for the
time being. However, CRP is neither specific nor sensitive for
the evaluation of COPD. Future longitudinal studies in well-
characterized COPD patients are warranted in order to
identify possible biomarkers that will help in the character-
ization of different phenotypes of the disease and predict
disease progression.73
Assessment of comorbidities
COPD patients are to great extent elderly, former or current
smokers, with increased systemic inflammation,74 factors
that are associated with significant comorbid diseases suchas cardiovascular disease, osteoporosis, cancer and depres-
sion.74 Several studies have shown that patients with COPD
present more comorbidities than matched controls without
COPD75 and these comorbidities account for a significant part
of health-care utilization.76 We are about to discuss some of
the most frequent comorbidities which may influence the
outcome of COPD patients.
The association between COPD, systemic inflammation
and cardiovascular mortality is very important since more
than one half of all patients with COPD die from cardio-
vascular causes and lung function is a predictor of all cause
and cardiac specific mortality.77 It is known that COPD
increases the risk of cardiovascular disease (i.e. athero-
sclerosis, ischemic heart disease, stroke and sudden cardiac
death) by two- to three-fold and it has been suggested that
persistent systemic inflammation that occurs in COPD may
contribute significantly to the pathogenesis of the cardio-
vascular abnormalities observed in COPD patients.25 Inter-
estingly, COPD patients present with increased risk for
cardiovascular morbidity and mortality especially at
younger age.78 COPD patients should be evaluated for
cardiovascular disease with the use of echocardiogram,
while pulmonary artery catheterization may be used in
cases where pulmonary hypertension is suspected. Trans-
thoracic echocardiography may be problematic in COPD
patients because hyperinflation limits its diagnostic accu-
racy.79 Furthermore, non-invasive assessment of coronary
artery disease in COPD by stress testing is difficult to
evaluate since such patients are limited by dyspnea on
exertion. Pharmacologic testing (including adenosine and
dipyridamole) may be associated with bronchoconstriction
and may also be avoided.79 When coronary disease is sus-
pected in COPD patients the diagnosis must be confirmed
with the use of invasive methods.
Osteoporosis is increased in patients with COPD, and has
multiple possible causes, including malnutrition, seden-
tarism, smoking, steroid treatment and systemic inflam-
mation. Incidence of osteopenia and osteoporosis are both
increased in more severe disease, and they are invariably
present in patients with low BMI and FFMI.80 Recently,
COPD has been recognized as an independent risk factor for
the identification of osteoporosis in men.81 Additional risk
factors include increased age and lower body weight and
a predictive model including the above three variables has
been proposed.81 Male COPD patients who are over 55 years
of age and/or weight less that 70 kg (154 lb) should undergo
a dual-energy X-ray absorptiometry testing and receive
therapy according to its result.81 The effects of the pres-
ence of osteoporosis in COPD patients are not only the
predisposition to painful vertebral fractures and the
disability costs, but also the impact in lung function by
altering the configuration of the chest wall. It has been
estimated that each thoracic vertebral fracture results in
a 10% decrease in vital capacity.52 Therefore, in cases in
which osteoporosis is likely to occur it is crucial to evaluate
and treat it properly.52
It has been shown that COPD is an independent risk
factor for lung cancer and that smokers who develop COPD
are in greater risk for lung cancer compared to smokers
without COPD.26 Chronic inflammation may play a role in
the pathogenesis of lung cancer as a tumor promoter by up-
regulating pro-oncogenes, and down regulate suppressor
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transformation.82 The risk for development of lung cancer
in COPD patients remains elevated for years after smoking
cessation.82 According to these observations COPD patients
are a possible target group that should be screened for the
early detection of lung cancer.26
Another frequent comorbidity in COPD patients is the
development of depression. It is a fact that COPD patients
often face major physical impairment and embarrassing
symptoms, including chronic dyspnea.83 Patients with
severe COPD are in even greater risk of developing
depression.83 The diagnosis and treatment of depression in
COPD patients are important, as depression by itself is
aggravated by worsening dyspnea and fatigue, diminishes
functional performance and exercise capacity and is asso-
ciated with impaired quality of life.84 A recent study has
shown that frequent exacerbators present higher depres-
sion scores compared to infrequent exacerbators.85
Recognizing and treating depression, besides improving
quality of life, may also indirectly decrease the risk of
exacerbations, since depressed patients have more diffi-
culty to learn and comply with treatment plans.86
Furthermore, treating depression may also improve the
outcome of acute exacerbations, as it has been shown that
depressed patients do not seek medical help early, which
leads to increased risk for poorer outcomes.86 Several tools
have been used to assess depression in patients with
chronic diseases, including the Hospital Anxiety and
Depression Scale and the Depression anxiety stress scale
which have been validated in COPD patients.87,88 COPD
patients with physical disability, severe dyspnea, and poor
quality of life, as well as those receiving long-term oxygen
therapy and those of low socioeconomic status, are more
susceptible to develop depression.88
Gastroesophageal reflux disease is common in patients
with severe COPD and a significant proportion of those
patients did not present symptoms or receive appropriate
treatment.89 Higher BMI was the only predictor of the
presence of Gastroesophageal reflux disease in those
patients.89 Furthermore, in a recent study, gastroesopha-
geal reflux symptoms were associated to the occurrence of
COPD exacerbations.90
Anemia represents another significant comorbidity in
severe COPD patients, and it is surprisingly even more
prevalent than polycythemia.91 Anemia is related to the
level of dyspnea and reduced exercise capacity in COPD
patients, whereas it is a predictor of survival in cohort
studies of severe COPD patients.91,92 The mechanism of
anemia development in COPD might be similar to that in
other chronic diseases, possibly related to erythropoietin
resistance.92
Comorbidities, especially cardiovascular, osteoporosis,
and depression, represent significant aspects of the global
management of the COPD patient in primary care. Those
complex comorbidities are also more likely to present in
COPD patients who are admitted to hospital compared to
patients without COPD.93 It is not clear whether comorbid
conditions make COPD patients more susceptible to the
consequences of COPD, or whether COPD increases the
patient’s susceptibility to those specific comorbidities.82
However, it is important to treat them aggressively in
patients with COPD, having in mind that most clinicalpractice guidelines do not modify or discuss the applica-
bility of their recommendations for older patients with
multiple comorbidities.94
Recognizing different phenotypes
COPD is a complex disease, including different types of
patients under the broad definition of chronic airflow
limitation that is not fully reversible and is produced by an
inflammatory response of the lungs to inhaled noxious
particles or gases.2 However, in clinical practice the disease
does not present as a single entity and the identification of
different phenotypes may be important for clinical
decisions.
Gender differences
Among the latest years, the prevalence and mortality of
COPD in female smokers seem to increase.95 Recent studies
have shown that disease manifestations differ between
men and women.96,97 Women with severe emphysema tend
to develop COPD at a younger age and usually have shorter
smoking history compared to men with disease of the same
stage.97 In a study of 53 male and 53 female COPD patients
matched for FEV1, despite the fact that they had less
comorbidities and better arterial blood gases (i.e. higher
PaO2 and lower PCO2), female patients presented with
lower BMI, worse exercise capacity, more impaired health-
related quality of life and a higher degree of dyspnea
compared to male patients.96 Furthermore, the risk of
death seems to be higher in women with severe COPD using
long-term oxygen therapy (LTOT) compared to men.98
The gender differences among COPD patients do not
concern only the symptoms of the disease but also the
different effects of several therapeutic interventions. For
example, a meta-analysis has shown that inhaled cortico-
steroids have more beneficial effects in women,99 whereas
a randomized clinical trial revealed that women present
little added benefit to long-term over short-term exercise
therapy compared to men.100 The above findings suggest
that gender should be taken into account in the everyday
assessment of COPD patients; further studies are needed in
order to identify interventions that may improve gender-
related outcomes.
Smoking habit
Tobacco smoke represents the most important risk factor
for the development of COPD.2 COPD patients who continue
to smoke have a more rapid decline in FEV1,
101 and are in
greater risk of developing lung cancer compared to COPD
patients who quit smoking.102 Current smokers present also
had higher levels of systemic inflammation (as expressed by
serum CRP levels) compared to ex-smokers,103 and have
a greater risk for hospital admission.104 Furthermore,
former smokers with COPD benefit more from the use of
inhaled corticosteroids, presenting lower all-cause
mortality.99 Importantly, a combination of a long-acting b2-
agonist and an inhaled corticosteroid exhibited more
prominent anti-inflammatory effects in ex-smokers
compared to current smokers.105 According to the above,
Table 2 Variables and point values used for the compu-
tation of the multidimensional BODE Index.40
Variable Points on BODE index
0 1 2 3
FEV1 (% of predicted) 65 50e64 36e49 <35
Distance walked
in 6 min (m)
350 250e349 150e249 <149
MMRC dyspnea scale 0e1 2 3 4
Body mass
index (kg/m2)
>21 21
FEV1: Forced expiratory volume in 1 s; MMRC: modified Medical
Research Council.
656 A.I. Papaioannou et al.the assessment of the smoking status of COPD patients is
necessary and smoking cessation interventions should be
promptly discussed with the primary care physician.
Exacerbation frequency
Exacerbations of COPD (ECOPD) are an important feature in
the natural history of COPD and it is important for the
attending physician to identify the frequency of these events
and to recognize the factors that may be associated with
them.106 It is well known that several risk factors are asso-
ciated with AECOPD, the most important being a history of
hospital admission for ECOPD, comorbidities, HRQoL,107
more severe disease108 and lower airway bacterial coloniza-
tion.109 ECOPD have a deleterious impact on COPD patients,
that is reflected on dramatic impairments of HRQoL.110
According to the number of ECOPD per year, COPD
patients can be considered as frequent exacerbators, with
different studies using different cut-off points of exacerba-
tions per year.111,112 It has been shown that frequent exac-
erbators have a significantly greater decline in FEV1,
111 and
they present higher mortality risk, especially those requiring
hospital admission.112 Despite the fact that the majority of
the evidence-based therapeutic interventions proposed by
the current guidelines are effective in the reduction of
ECOPD,1,2 the identification of COPD patients who present
frequent exacerbations is important, since those patients
are at greater need for more aggressive treatment.
Emphysema and chronic bronchitis
The most commonly discussed phenotypes of COPD are the
well-known images of the patients characterized predomi-
nantly by emphysema (the ‘‘pink puffers’’) and the patients
characterized mainly by the presence of chronic bronchitis
(‘‘blue bloaters’’). The ‘‘blue bloaters’’ are usually charac-
terized by hypoxemia and hypercapnia, which are compli-
cated by pulmonary hypertension and right heart failure; the
‘‘pink puffers’’ are characterized by cachexia, quite normal
blood gases and greater dyspnea. Despite the fact that
emphysema can occur in both phenotypes, it is more
frequently observed in the ‘‘pink puffer’’.113 The introduc-
tion of high resolution computed tomography (HRCT) has
brought a newdimension to the studyof COPD, as it offers the
opportunity to study the pathologic processes involved in
structural changes within the lung and to investigate the
severity, extension and distribution of the lung destruc-
tion.7,114 Besides the well-studied aforementioned features
of the two phenotypes, recent studies have studied the
differences between patients with and without emphysema
on HRCT; COPD patients with HRCT-confirmed emphysema
are characterized by more severe lung function impairment,
more intense airway inflammation and possibly more serious
systemic dysfunction.115 Further longitudinal studies are
needed in order to assess the impact of the two phenotypes
on the outcome of COPD patients.
Genomics in COPD
It is generally accepted that cigarette smoke is the major
cause of COPD.2 However, the fact that only 20% of smokerswill develop COPD shows that the disease develops from
a gene-environment interaction.2 Furthermore, population
studies have shown a familial aggregation of lung function
and COPD clustering within families.116 Plenty of research
has been devoted to the identification of genes that are
implicated in COPD development. To date a1-antitrypsin
deficiency is the only documented genetic risk factor and is
related to early COPD onset.117 Serum a1-antitrypsin levels
should be evaluated in patients with minor smoking history
and/or early disease onset (i.e. <45 years) as well as in
those who have a family history of the disease.2 A number
of other genes have been proposed to be implicated to
COPD development, such as matrix metalloproteinase
(MMP)-9, MMP-2, tumor necrosis factor-a, transforming
growth factor-b and superoxide dismutase.117 However,
since the results of genetic association studies are largely
inconsistent, and the role of those genetic variants in COPD
development has not been definitively identified, the
detection of alterations in such genes cannot be suggested
for application in clinical practice yet.
Multidimensional grading systems
A multidimensional disease, such as COPD, needs multidi-
mensional grading systems in order to describe better the
health status of the individual patients and define better
their prognosis.40,113 A staging system which was recently
reported is the BODE index, a composite measure that
incorporates body composition (Body mass index), airflow
limitation (Obstruction, expressed by the FEV1% pre-
dicted), Dyspnea (expressed with the modified MRC scale),
and Exercise capacity (as expressed with the 6-minute
walking distance).40 The method for performing the scoring
of the BODE index is easy and does not require special
equipment (Table 2). The score ranges from 0 to 10,
increasing with disease severity, and has been shown to be
a good predictor of hospitalization as well as of all cause
and respiratory mortality in COPD patiens.40,118 Exacerba-
tions have significant Impact on the BODE index119 and
increases in the BODE index are associated with mortality
in severe COPD.120 The latest findings support that the
BODE index can be a practical instrument for outcomes
assessment of COPD that may be easily implemented in
clinical practice.
Table 3 Variables that may be useful for the global assessment of the COPD patient, both in the clinical and in the inves-
tigational level.
Type of assessment Clinical Investigational
Pulmonary function tests Post-bronchodilator FEV1, FEV1/FVC ratio DLCO, IC/TLC
Dyspnea MMRC scale Borg scale
Body composition BMI FFM, FFMI
Exercise capacity 6-Minute Walk Test, Shuttle Walk Testa Cardiopulmonary exercise testing
Radiological evaluation Chest X-ray HRCT
(necessary for referral for LVRS)
Quality of Life SGRQ SF-36
Comorbidities
Cardiovascular disease
Osteoporosis
Depression
Lung cancer
Anemia
Gastroesophageal reflux disease
Phenotypes
Smoking habit
Exacerbation frequency
Gender
Presence of emphysema
FEV1: Forced expiratory volume in 1 s; FVC: Forced expired vital capacity; DLCO: Diffusing lung capacity for carbon monoxide; IC:
Inspiratory capacity; TLC: Total lung capacity; MMRC: Modified Medical Research Council; BMI: Body mass index; FFM: Fat free mass;
FFMI: Fat free mass index; 6MWD: 6-Minutes walking distance; LVRS: Lung-volume reduction surgery; SGRQ: Saint George respiratory
Questionnaire; SF-36: Study short form 36.
a Depends on availability.
Global assessment of the COPD patient 657Conclusions
COPD is a diverse disease entity with multiple dimensions
that uniquely define the patient’s performance, morbidity
and mortality. Therefore, the global assessment of an
affected patient should include different aspects of the
consequences of this disorder, beyond the ‘‘gold-standard’’
assessment of airflow limitation (Table 3). Quantification of
the patient’s dyspnea, body composition as expressed by
BMI, simple measures of exercise capacity such as the
6MWD, assessment of comorbidities and identification of
characteristics related to different phenotypes are features
that may lead to more optimal management of such
patients. Biomarkers represent attractive options but are
far from implementation in COPD. Longitudinal studies
including properly characterized patients are needed in
order to identify which of the aforementioned features are
more important for the outcome of COPD patients.
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